Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes

James E. Haddow1,2*, Wendy Y. Craig3, Louis M. Neveux1,2, Glenn E. Palomaki1,2, Geralyn Lambert-Messerlian1, Fergal D. Malone4,5, Mary E. D’Alton4, First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium

1 Department of Pathology and Laboratory Medicine, Division of Medical Screening and Special Testing, Women and Infants Hospital and Alpert Medical School of Brown University, Providence, Rhode Island, United States of America, 2 Savjani Institute for Health Research, Windham, Maine, United States of America, 3 Maine Medical Center Research Institute, Scarborough, Maine, United States of America, 4 Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, University College of Physicians and Surgeons, New York, New York, United States of America, 5 Department of Obstetrics & Gynecology, Royal College of Surgeons in Ireland, Dublin, Ireland, United Kingdom

¶ Membership of the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium is listed in the Acknowledgments.

* jhaddow@ipmms.org

Abstract

Several studies have now reported associations between gestational diabetes mellitus (GDM) and low free thyroxine (FT4) during the second and third trimesters, but not in the first trimester. The present study further examines relationships between low FT4, maternal weight, and GDM among women in the FaSTER (First and Second Trimester Evaluation of Risk) Trial, in an effort to determine the extent to which thyroid hormones might contribute to causality. The FaSTER cohort includes 9351 singleton, euthyroid women; 272 of these women were subsequently classified as having GDM. Thyrotropin (TSH), FT4, and thyroid antibodies were measured at 11–14 weeks’ gestation (first trimester) and 15–18.9 weeks’ gestation (second trimester). An earlier report of this cohort documented an inverse relationship between FT4 in the second trimester and maternal weight. In the current analysis, women with GDM were significantly older (32 vs. 28 years) and weighed more (75 vs. 64.5 kg). Maternal weight and age (but not TSH) were significantly associated univariately with FT4 (dependent variable), in the order listed. Second trimester FT4 odds ratios (OR) for GDM were 2.06 [95% CI 1.37–3.09] (unadjusted); and 1.89 [95% CI 1.26–2.84] (adjusted). First trimester odds ratios were not significant: OR 1.45 [95% CI 0.97–2.16] (unadjusted) and 1.11 [95% CI 0.74–1.62] (adjusted). The second trimester FT4/GDM relationship thus appeared to strengthen as gestation progressed. In FaSTER, high maternal weight was associated with both low FT4 and a higher GDM rate in the second trimester. Peripheral deiodinase activity is known to increase with high caloric intake (represented by high weight). We speculate that weight-related low FT4 (the metabolically inactive prohormone) is a marker for deiodinase activity, serving as a substrate for conversion of FT4 to free triiodothyronine (FT3), the active hormone responsible for glucose-related metabolic activity.

PLOS ONE | DOI:10.1371/journal.pone.0149065 February 24, 2016 1/1
directly to me by Mary D’Alton. (P.I.). No other unpublished data have been transferred to me by Dr. D’Alton. The minimal dataset from our paper are now uploaded into the Supporting Information file in the present paper, with agreement from Dr. D’Alton and me. Individual authors and affiliations within the Research Consortium are listed in the acknowledgement section of our paper, along with the lead author of the Consortium.

Funding: The FaSTER dataset was funded by Grant Number R01 HD 38652 from the National Institute of Child Health and Human Development (https://www.nih.gov/Pages/index.aspx) MED. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The present analysis of the FaSTER dataset was carried out by investigators in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital and the Alpert Medical School at Brown University.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

In the United States, approximately 4% of pregnancies are diagnosed as having gestational diabetes mellitus (GDM) [1]. GDM resolves after delivery but recurs 30–50% of the time with subsequent pregnancies; longer term, type 2 diabetes occurs in up to 70% of women with a previous history of GDM [2, 3]. The pattern of post-delivery resolution of GDM, followed by recurrence with a subsequent pregnancy, suggests pregnancy-related stress. In spite of well-known associations with glucose intolerance, β-cell dysfunction, and insulin resistance, the pathogenesis of GDM is incompletely understood [4, 5]. Recently, several studies among euthyroid women have reported associations between GDM and low free thyroxine (fT4) during the second and third trimesters [6–9] but not in the first trimester [7, 9, 10] offering a clue that thyroid hormones may provide further insight into pathogenesis. Guzman-Gutiérrez et al. have recently proposed that the low level of fT4 associated with GDM may be compensated by increased placental availability of T3/T4 via elevation in the activity of thyroid hormone transporters and/or reduction in deiodinases in the feto-placental circulation [11].

The present study examines in greater depth the relationship between free thyroxine (fT4) concentration and gestational diabetes mellitus (GDM) among euthyroid women with a singleton pregnancy who participated in the First and Second Trimester Evaluation of Risk (FaSTER) trial [12]. In the initial analysis of that cohort in 2008, Cleary-Goldman et al explored whether relationships might exist between hypothyroxinemia (fT4 concentrations below the 2.5th percentile) and several pregnancy/delivery complications [7]. Among euthyroid women, they found an association between hypothyroxinemia and subsequent GDM at 15–18.9 weeks’ gestation, but not at 11–14 weeks’ gestation. A later analysis of that same dataset focused on the impact of high fT4 concentrations (highest quintile) on birthweight at 15–18.9 weeks’ gestation and noted incidentally that the frequency of gestational diabetes ranged from 5% in the lowest fT4 quintile to 1.3% in the highest fT4 quintile [13].

Also relevant to the present study is the reciprocal relationship between fT4 and maternal weight documented in an earlier FaSTER report [14]. Weight and/or body mass index (BMI) are both established risk factors for GDM and need to be taken into account (along with other covariates) when examining the fT4/GDM relationship [15, 16]. The present analysis examines the fT4/GDM relationship identified in the FaSTER trial by exploring the extent to which fT4 might be an independent risk factor for GDM and speculating on how thyroid hormones might contribute to causality.

Materials and Methods

The multicenter FaSTER trial, a National Institute of Child Health and Human Development-sponsored study, was a prospective multicenter investigation of singleton pregnancies from an unselected obstetric population at 15 centers throughout the United States, beginning in October 1, 1990 and ending in December 31, 2002 [7, 13, 14, 17]. Institutional review board approval for this study was granted by the Columbia University Medical Center, New York and by Women and Infants Hospital, Brown University, Rhode Island. After written informed consent was obtained, patients were enrolled between 10 3/7 and 13 6/7 weeks of gestation; weight and height were recorded on that occasion. All subjects had a live singleton intrauterine pregnancy without evidence of anencephaly or cystic hygroma, confirmed by ultrasonography at the time of trial enrollment.

Maternal serum samples were collected at two intervals during early pregnancy. At five recruitment centers, participants were asked to give supplementary consent to allow use of residual sample and pregnancy-related information for additional research. Women whose pregnancies were affected by Down syndrome or other chromosome structural abnormalities
were excluded. Among women who consented, inclusion criteria for the present study required: 1) thyrotropin (TSH) and free T4 measurement available and gestational age established by ultrasound (10,074 women), 2) no known thyroid disease (9,670 women), 3) available weight and height (9,630 women), and 4) TSH measurements between 2nd and 98th centiles (9,351 women) at 11–14 weeks’ gestation (0.008–4.17 IU/L), and at 15–18.9 weeks’ gestation (0.05–3.80 IU/L).

Post-delivery follow-up was performed by the research coordinator at each site or by telephone interview. A single perinatologist and a pediatric geneticist reviewed maternal and pediatric medical records for the following patient subsets: abnormal first and/or second trimester screening, adverse obstetric or pediatric outcomes, and 10% of normal subjects randomly selected from the trial database. A purpose-designed computerized tracking system with up to 10 contacts per subject was used to ensure complete outcome collection. Pregnancy and pediatric outcomes were obtained in more than 98% of cases. Gestational diabetes was classified as two abnormal values on a 3-hour glucose challenge test.

Samples were stored at -80°C. Levels of TSH, free T4 and thyroperoxidase (TPO) antibodies were measured between July 2004 and May 2005 using the Immulite 2000 methodology (Siemens Medical Solutions Diagnostics, Tarrytown, NY). Normative data involving these analytes have been published separately [17]. The lower limit for interpreting TSH measurements was 0.01 mIU/L. Long-term coefficients of variation were 5.3%, 6.9% and 3.8% at TSH concentrations of 0.53, 4.5 and 21.9 mU/L; 8.1%, 6.5% and 7.9% at free T4 concentrations of 11.6, 23.2 and 41.2 pmol/L; 2.5%, 6.6% and 5.0% at TPO antibody concentrations of 30, 39 and 546 IU/mL.

Statistical Analyses

Analyses included descriptive statistics, t-tests for continuous variables, and chi square tests for categorical variables. We used stepwise regression to adjust fT4 for the covariates age, weight, and TSH, after logarithmic transformation. We used linear regression to establish the relationship between GDM and the variables age, weight, and TSH; p-values in the figure are for slope significance (Fig 1). We defined unadjusted and adjusted odds ratios for GDM by comparing rates at the first fT4 decile vs. the remaining deciles. Statistical analyses were performed using SAS 9.4 (Cary, NC, USA).

Results

Table 1 shows selected characteristics of 9,079 women without GDM compared to 272 women with GDM (TSH 2nd to 98th centile). Women with GDM are older, weigh more, deliver earlier, and a greater percentage smokes cigarettes. Table 2 shows that median TSH and fT4 are lower at 15–18.9 weeks’, but not at 11–14 weeks’ gestation. The rate of TPO antibody positivity does not differ significantly between the two groups.

Table 3 applies stepwise regression to examine interactions between fT4 (dependent variable) and other characteristics in Tables 1 and 2 that differ significantly between women with and without GDM. Age and weight show the strongest interactions with fT4. TSH shows only weak interaction ($r^2 = 0.0014$) but is included on the list of variables to be considered in adjusting the fT4-GDM relationship, due to its known association with fT4. When the lowest fT4 decile is compared with the 2nd-10th deciles at 15–18.9 weeks’ gestation, the odds ratio (OR) for GDM is 2.06 [95% CI 1.37–3.09] (unadjusted); and 1.89 [95% CI 1.26–2.84] (adjusted for weight, age, and TSH). Adding TPO antibody to the adjustment model does not alter the relationship [1.87 (1.24–2.81)]. At 11–14 weeks’ gestation, the OR for GDM is 1.45 [95% CI 0.97–2.16] (unadjusted); and 1.11 [0.74–1.65] (adjusted).
Fig 1 shows that weight (Fig 1A), age (Fig 1B), and fT4 (Fig 1C) are associated univariately with GDM in decreasing order of significance. TSH (Fig 1D) is not significantly associated.

The dashed line in Fig 1C indicates that the association between fT4 and GDM remains significant after adjustment for age, weight, and TSH.

Discussion

An inverse relationship between fT4 and weight during pregnancy has been recognized for several years [18–20], including an association between low fT4 and high weight in the second trimester among euthyroid women in the FaSTER trial [14]. In a separate FaSTER analysis, fT4 was found once again to decrease with increasing weight among hypothyroid women being treated with L-thyroxine to maintain a euthyroid state, suggesting a link between weight and deiodinase activity [21]. In the present FaSTER analysis, high maternal weight and low fT4 are both associated with increased GDM risk (Fig 2).
Table 1. Characteristics of women with and without gestational diabetes.

| Characteristic                         | No GDM | GDM  | P     |
|---------------------------------------|--------|------|-------|
| Participating Women (n)               | 9,079  | 272  | N/C   |
| Gestational age (weeks)               | 16.1 (0.9) | 16.1 (0.8) | 0.37  |
| Age (years)                           | 28.0 (5.5) | 32.0 (5.6) | <0.0001 |
| Weight (kg)                           | 64.5 (14.2) | 75.0 (21.3) | <0.0001 |
| Education (years)                     | 14.6   | 14.6 | 0.67  |
| Education (% ≤12 years)               | 18.1   | 15.4 | 0.21  |
| Primigravid (%)                       | 41.9   | 39.7 | 0.47  |
| Smokes cigarettes (%)                 | 3.0    | 5.1  | 0.04  |
| Gestational age at delivery (weeks)   | 39.1 (2.2) | 38.7 (2.0) | <0.0001 |
| Gestational age (% <37 weeks)         | 7.0    | 10.3 | 0.04  |
| Gestational age (% <34 weeks)         | 2.3    | 2.9  | 0.52  |
| Birthweight (grams)                   | 3,401 (510) | 3,430 (608) | 0.33  |
| Birthweight (% <2500 grams)           | 4.9    | 5.9  | 0.47  |
| Birth weight (% ≥4000 grams)          | 8.7    | 11.0 | 0.18  |

*All characteristics are reported as Median (SD) unless specified otherwise

doi:10.1371/journal.pone.0149065.t001

Table 2. Thyrotropin (TSH), free thyroxine (fT4) and thyroperoxidase (TPO) antibodies among women with and without gestational diabetes (GDM).

|                                      | No GDM          | GDM            | P     |
|--------------------------------------|-----------------|----------------|-------|
| 11–14 weeks' gestation*              |                 |                |       |
| TSH (mIU/L)                          | 1.05 (0.40)     | 0.99 (0.38)    | 0.46  |
| fT4 (pmol/L)                         | 14.19 (0.13)    | 13.80 (0.09)   | 0.30  |
| TPO antibody >35 IU (%)              | 8.6             | 9.2            | 0.72  |
| 15–18.9 weeks' gestation*            |                 |                |       |
| TSH (mIU/L)                          | 1.23 (0.26)     | 1.15 (0.30)    | 0.026 |
| fT4 (pmol/L)                         | 13.03 (0.14)    | 12.38 (0.10)   | <0.01 |
| TPO antibody >35 IU (%)              | 8.1             | 9.2            | 0.53  |

*values reported as Median (log SD), unless specified otherwise

doi:10.1371/journal.pone.0149065.t002

Table 3. Extent to which variables that differ significantly between women with and without gestational diabetes might influence fT4 concentration (9,079 women without gestational diabetes).

| Variable       | Partial r² |
|----------------|------------|
| Age*           | 0.0283     |
| Weight*        | 0.0136     |
| TSH*           | 0.0014     |
| Education      | 0.0013     |
| Smoking        | 0.0001     |

*Data transformed logarithmically prior to analysis

doi:10.1371/journal.pone.0149065.t003
Studies from several centers between 2000 and 2015 report that low fT4 levels are significantly associated with GDM in the second and third trimesters [6–9], but not in the first [7, 9, 10]. In the FaSTER dataset, a significant relationship is also present between fT4 and GDM during the second trimester (15–18.9 weeks’ gestation), which does not, however, reach significance in the first trimester, suggesting a progression toward glucose intolerance as pregnancy progresses.

Thyroid hormones play an important role in glucose metabolism, but triiodothyronine (T3), rather than T4, is the biologically active hormone primarily responsible for glucose-related metabolic activity [22, 23]. Hyperglycemia typically occurs when thyroid hormone levels are elevated, rather than low. When hyperthyroidism develops in the presence of diabetes, for example, the attendant refractory hyperglycemia accompanying type 2 diabetes is reversed only after a return to the euthyroid state [22]. Given this circumstance, it is not immediately obvious why low fT4 should qualify as a candidate agent for contributing to GDM risk in euthyroid women.

A biologically plausible explanation for this apparent paradox comes from two population-based studies in pregnant women that found not only a reciprocal fT4/BMI relationship, but also a direct relationship between maternal free T3 (fT3) and BMI [18, 19]. Among 5,072 Finnish women, fT4 decreased, and fT3 increased, monotonically as BMI increased, each changing about 5% between a BMI of <20 kg/m² and >30 kg/m² (both P <0.001) [19]. Among 3,592 pregnant women in London, multiple regression analysis showed a reciprocal relationship between Log₁₀ fT4 and BMI and a direct relationship between Log₁₀ fT3 and BMI (both P <0.0001) [18]. In both studies, therefore, lower fT4 associated with obesity appears to occur in conjunction with higher fT3.

Two other observational studies add further insight, by examining fT4 levels and fT3/fT4 ratios in relation to biometric and metabolic parameters in euthyroid pregnancies [24, 25]. The fT3/fT4 ratios serve as a proxy for peripheral deiodinase activity. Both studies documented not only a reciprocal relationship between fT4 and BMI, but also a direct relationship between the fT3/fT4 ratio and BMI, indicating increased peripheral deiodinase activity.
In the first study, Bassols et al recruited 321 women with singleton pregnancies at 24–28 weeks’ gestation [24]. Women with GDM, preeclampsia, and fetal malformations or asphyxia were excluded. The highest hemoglobin A1c (HbA1c), fasting plasma insulin (FPI), homeostasis model assessment-insulin resistance (HOMA-IR), maternal BMI, placental weight, and triglyceride levels occurred in the lowest fT4 quintile and in the highest fT3/fT4 ratio quintile. With the exception of placental weight, these relationships were stronger when analyzed by fT3/fT4 ratio than by fT4 alone. In the second, Knight et al studied 965 women without either GDM or known thyroid disease and documented significant inverse correlations between fT4 and maternal BMI, HbA1c, FPI, HOMA-IR, and triglycerides, at 28 weeks’ gestation [25]. Once again, direct correlations of stronger significance were found between the fT3/fT4 ratio and these same metabolic parameters.

Beginning in the 1970s, it was recognized that most circulating T3 was generated via peripheral conversion of T4 and that a direct correlation existed between T3 and body weight in non-pregnant adults [26]. All T4 and 20% of T3 is produced in the thyroid gland; the remaining 80% of T3 is converted peripherally by deiodinase activity via mono-deiodination of T4 [27]. Peripheral conversion of T4 to T3 decreases dramatically in the presence of extreme caloric deprivation [28–31] and increases with overfeeding [32], indicating that peripheral deiodinase activity is highly responsive to acute changes in caloric intake. In 2014, Agnihothri et al carried out a 12 month reduced calorie dietary intervention study in non-pregnant adults. T3 decreased significantly with longer term weight loss, and the T3/fT4 ratio decreased significantly with >5% loss of body weight, leading to the conclusion that decreased peripheral conversion of T4 to T3 at least partially explained the longer term dietary and weight changes in thyroid hormone homeostasis [33].

In the above human studies, peripheral deiodinase activity could only be assessed via surrogate measures in serum or plasma (e.g., T3/T4 ratios, reverse T3), due to the impracticality of obtaining tissue samples. Direct measurements of hepatic deiodinase-1 mRNA and deiodinase-1 activity in animal studies, however, support conclusions drawn from surrogate measurements. A high fat diet in wild type mice, for example, induces not only lower serum T4 and higher T3 and T3/T4 ratios, but also higher deiodinase-1 mRNA and activity in the liver [34]. Although the FaSTER trial did not include a dietary assessment, higher weight is a reasonable indicator of over-nutrition. Women were early in the second trimester at the time of sampling, and most were likely following their usual dietary routines and caloric intake. The reciprocal relationship between fT4 and maternal weight observed in FaSTER and other studies [18, 19, 24, 25], therefore, should reflect a generally steady dietary state within the pregnancy population. A recent FaSTER analysis documented a similar reciprocal fT4/weight relationship among 306 pregnant women being treated for hypothyroidism [21].

An important limitation of the present study is that fT3 was not measured as part of the original study’s protocol, and samples are no longer available to carry out retrospective analyses. As a consequence, it has been necessary to rely on results from other studies to fully interpret our findings. Strengths include a large cohort of pregnancies, with fT4 and TSH measured on all of the women and with complete ascertainment of GDM cases, along with relevant demographic data. Reference data from the FaSTER dataset have been published for fT4 and TSH, verifying reliable performance [7, 13, 14, 17]. Documentation of assay performance and availability of a large study population are both important, because direct immunoassays for fT4 are occasionally affected by altered concentrations of binding proteins, such as albumin and thyroxine binding globulin.

In this study, we report a new finding (Fig 3) that links obesity with induction of triiodothyronine (T3), a candidate causal agent contributing to gestational diabetes among women with normal thyroid gland function (euthyroid); T3 is the hormonal product responsible for
stimulating endogenous glucose production. In the present circumstance, normal amounts of thyroxine (T4), the inactive thyroid hormone precursor, are produced by the gland. Peripheral deiodinase activity \( \text{(e.g., liver, muscle)} \) then uses T4 as its substrate to produce the active hormone (T3). Obesity induces increased deiodinase activity, as indicated by a combination of higher T3 and lower T4 levels. Our study uses free T4 levels as the marker for deiodinase activity; T3 was not available in our study (please see limitations, above). At present, ectopic accumulation of fat in liver and muscle associated with over-nutrition is the best understood causal agent for insulin resistance and type 2 diabetes \([35]\). In our study, increased caloric intake is also unifying feature, in this case connecting higher weight on the one hand with deiodinase activity and gestational diabetes on the other. It thus appears that over-nutrition might predispose to both insulin resistance (ectopic fat) and endogenous glucose production (increased deiodinase), adding another dimension to the complexities of gestational diabetes.

**Supporting Information**

S1 Dataset. Dataset forming the basis for analyses in the FaSTER trial for the present study.

(XLS)

**Acknowledgments**

The members of the FASTER Research Consortium were as follows: K. Welch and R. Denchy, Columbia University, New York; F. Porter, M. Belfort, B. Oshiro, L. Cannon, K. Nelson, C. Loucks, and A. Yoshimura, University of Utah, Salt Lake City, and Intermountain Health Care Perinatal Centers, Salt Lake City, Provo, and Ogden; D. Luthy and S. Coe, Swedish Medical
Center, Seattle; D. Schmidt and J. Esler, William Beaumont Hospital, Royal Oak, Michigan; G. Hankins, G. Saade, and J. Lee, University of Texas Medical Branch, Galveston; K. Eddleman and Y. Kharbutli, Mount Sinai Medical Center, New York; I. Merkatz and S. Carter, Montefiore Medical Center, Bronx, New York; J. Hobbins and L. Schultz, University of Colorado Health Science Center, Denver; M. Paidas and J. Borsuk, New York University Medical Center, New York; B. Isquith and B. Berlin, Tufts University, Boston; C. Duquette, Brown University, Providence, Rhode Island; R. Baughman, university of North Carolina, Chapel Hill; J. Hanson and F. de la Cruz, National Institute of Child Health and Human Development, Bethesda, Maryland; T. Tripp, D. Emig, and L. Sullivan, DM-STAT, Medford, MA; J. Bestwick, Wolfson Institute of Preventive Medicine, London. **Independent Ultrasound Quality Assurance Committee:** A. Abuhamad, Eastern Virginia Medical School, Norfolk and J. Copel, Yale University School of Medicine, New Haven, CT. **Independent Data-Monitoring Committee:** J. Goldberg, California Pacific Medical Center, San Francisco; J. Haddow, Foundation for Blood Research, Scarborough, ME; A. Hogg, Magee-Women’s Hospital, Pittsburgh, PA; M. Mennuti, University of Pennsylvania, Philadelphia.

**Lead Author for this Group:** Mary D’Alton, md511@columbia.edu

**Author Contributions**

Conceived and designed the experiments: JEH. Analyzed the data: LMN GEP. Wrote the paper: JEH WYC LMN GEP GL-M FDM MED.

**References**

1. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 2007; 30 Suppl 2:S251–60. doi: 10.2337/dc07-s225 PMID: 17596481.

2. Rauh-Hain JA, Rana S, Tamez H, Wang A, Cohen B, Cohen A, et al. Risk for developing gestational diabetes in women with twin pregnancies. J Matern Fetal Neonatal Med. 2009; 22(4):293–9. doi: 10.1080/14767050802663194 PMID: 19460713.

3. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002; 25(10):1862–8. PMID: 12351492.

4. Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol. 1993; 264(1 Pt 1):E60–7. PMID: 8430789.

5. Buchanan TA, Xiang A, Kjos SL, Watanabe R. What is gestational diabetes? Diabetes Care. 2007; 30 Suppl 2:S105–11. doi: 10.2337/dc07-s201 PMID: 17596457.

6. Olivieri A, Valensise H, Magnani F, Medda E, De Angelis S, D’Archivio M, et al. High frequency of antithyroid autoantibodies in pregnant women at increased risk of gestational diabetes mellitus. Eur J Endocrinol. 2000; 143(6):741–7. PMID: 11124856.

7. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008; 112(1):85–92. Epub 2008/07/02. [pii]. PMID: 18591312.

8. Velkoska Nakova V, Krstevska B, Dimitrovski C, Simeonova S, Hadzi-Lega M, Serafimoski V. Prevalence of thyroid dysfunction and autoimmunity in pregnant women with gestational diabetes and diabetes type 1. Prilozi / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences. 2010; 31(2):51–9. PMID: 21259277.

9. Oguz A, Tuzun D, Sahin M, Usluogullari AC, Usluogullari B, Celik A, et al. Frequency of isolated maternal hypothyroxinemia in women with gestational diabetes mellitus in a moderately iodine-deficient area. Gynecol Endocrinol. 2015; 31(6):741–7. doi: 10.3109/09513590.2015.1054801 PMID: 26190538.

10. Agarwal MM, Dhatt GS, Punnose J, Bishawi B, Zayed R. Thyroid function abnormalities and antithyroid antibody prevalence in pregnant women at high risk for gestational diabetes mellitus. Gynecol Endocrinol. 2008; 24(5):261–6. doi: 10.1080/09513590600630470 PMID: 18785147.

11. Guzman-Gutierrez E, Veas C, Leiva A, Escudero C, Sobrevia L. Is a low level of free thyroxine in the maternal circulation associated with altered endothelial function in gestational diabetes? Frontiers in
pharmacology. 2014; 5:136. doi: 10.3389/fphar.2014.00136 PMID: 24936187; PubMed Central PMCID: PMC4047677.

12. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005; 353(19):2001–11. PMID: 16282175.

13. Haddow JE, Craig WY, Neveux LM, Haddow HR, Palomaki GE, Lambert-Messerlian G, et al. Implications of high free thyroxine (FT4) concentrations in euthyroid pregnancies: the FaSTER trial. J Clin Endocrinol Metab. 2014; 99(6):2038–44. doi: 10.1210/jc.2014-1053 PMID: 24606107; PubMed Central PMCID: PMC4037729.

14. Haddow JE, Craig WY, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, et al. Impact of adjusting for the reciprocal relationship between maternal weight and free thyroxine during early pregnancy. Thyroid. 2013; 23(2):225–30. doi: 10.1089/thy.2012.0440 PMID: 23136959.

15. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007; 30(8):2070–6. doi: 10.2337/dc06-2559a PMID: 17416786.

16. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obes Rev. 2009; 10(2):194–203. doi: 10.1111/j.1467-789X.2008.00541.x PMID: 19055539.

17. Lambert-Messerlian G, McClain M, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, et al. First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol. 2008; 199(1):62 e1–6. PMID: 18585522.

18. Ashoor G, Kametas NA, Akelekar R, Giudisco J, Nicolaides KH. Maternal thyroid function at 11–13 weeks of gestation. Fetal Diagn Ther. 2010; 27(3):156–63. doi: 10.1159/000331301 PMID: 20413976.

19. Mannisto T, Surcel HM, Ruokonen A, Vaarasmaa M, Pouta A, Bloigu A, et al. Early pregnancy reference intervals of thyroid hormone concentrations in a thyroid antibody-negative pregnant population. Thyroid. 2011; 21(3):291–8. Epub 2011/01/25. doi: 10.1089/thy.2010.0337 PMID: 21254924.

20. Bestwick JP, John R, Maina G, Guarral-V, Joorn M, Wald NJ, et al. Thyroid stimulating hormone and free thyroxine in pregnancy: expressing concentrations as multiples of the median (MoMs). Clin Chim Acta. 2014; 430:33–7. Epub 2014/01/02. doi: 10.1016/j.cca.2013.12.030 PMID: 24380740.

21. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D’Alton ME. An inverse relationship between weight and free thyroxine during early gestation among women treated for hypothyroidism. Thyroid. 2015; 25(8):949–53. doi: 10.1089/thy.2015.0085 PMID: 26061605.

22. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr Pract. 2009; 15(3):254–62. PMID: 19364696.

23. Pisarev MA. Interrelationships between the pancreas and the thyroid. Current opinion in endocrinology, diabetes, and obesity. 2010; 17(5):437–9. doi: 10.1097/MED.0b013e32833e0750 PMID: 20717019.

24. Bassols J, Prats-Puig A, Soriano-Rodriguez P, Garcia-Gonzalez MM, Reid J, Martinez-Pascual M, et al. Lower free thyroxin associates with a less favorable metabolic phenotype in healthy pregnant women. J Clin Endocrinol Metab. 2011; 96(12):3717–23. Epub 2011/09/16. doi: 10.1210/jc.2011-1784 PMID: 21917863.

25. Knight B, Shields B., Hattersley A., Vaidya B. Thyroid hormone levels in normal pregnancy are associated with altered metabolic parameters. Eur Thyroid J. 2012; 1(suppl 1):89.

26. Bray GA, Fisher DA, Chopra IJ. Relation of thyroid hormones to body-weight. Lancet. 1976; 1 (7971):1206–8. PMID: 58256.

27. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987; 316(13):764–70. doi: 10.1056/NEJM198703263161302 PMID: 3821822.

28. Vagenakis AG, Burger A, Portnay GI, Rudolph M, O’Brain JT, Azizi F, et al. Diversion of peripheral thyroxine metabolism from activating to inactivating pathways during complete fasting. J Clin Endocrinol Metab. 1975; 41(1):191–4. doi: 10.1210/jcem-41-1-191 PMID: 1150863.

29. Spaulding SW, Chopra IJ, Sherwin RS, Lyal SS. Effect of caloric restriction and dietary composition of serum T3 and reverse T3 in man. J Clin Endocrinol Metab. 1976; 42(1):197–200. doi: 10.1210/jcem-42-1-197 PMID: 1249190.

30. Carlson HE, Drenick EJ, Chopra IJ, Hershman JM. Alterations in basal and TRH-stimulated serum levels of thyrotropin, prolactin, and thyroid hormones in starved obese men. J Clin Endocrinol Metab. 1977; 45(4):707–13. doi: 10.1210/jcem-45-4-707 PMID: 410822.
31. Suda AK, Pittman CS, Shimizu T, Chambers JB Jr., The production and metabolism of 3,5,3'-triiodothyronine and 3,3',5-triiodothyronine in normal and fasting subjects. J Clin Endocrinol Metab. 1978; 47 (6):1311–9. doi: 10.1210/jcem-47-6-1311 PMID: 263351.

32. Danforth E Jr., Horton ES, O'Connell M, Sims EA, Burger AG, Ingbar SH, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest. 1979; 64(5):1336–47. doi: 10.1172/JCI109590 PMID: 500814; PubMed Central PMCID: PMC371281.

33. Agnihothri RV, Courville AB, Linderman JD, Smith S, Brychta R, Remaley A, et al. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibit its peripheral conversion. Thyroid. 2014; 24(1):19–26. doi: 10.1089/thy.2013.0055 PMID: 23902316; PubMed Central PMCID: PMC3887425.

34. Pelletier P, Gauthier K, Sideleva O, Samarut J, Silva JE. Mice lacking the thyroid hormone receptor-alpha gene spend more energy in thermogenesis, burn more fat, and are less sensitive to high-fat diet-induced obesity. Endocrinology. 2008; 149(12):6471–86. doi: 10.1210/en.2008-0718 PMID: 18719022.

35. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(12):1131–41. doi: 10.1056/NEJMra1011035 PMID: 25229917.